116 related articles for article (PubMed ID: 15214434)
1. Partial alanine scan of mast cell degranulating peptide (MCD): importance of the histidine- and arginine residues.
Buku A; Mendlowitz M; Condie BA; Price JA
J Pept Sci; 2004 Jun; 10(6):313-7. PubMed ID: 15214434
[TBL] [Abstract][Full Text] [Related]
2. Histamine-releasing activity and binding to the FcepsilonRI alpha human mast cell receptor subunit of mast cell degranulating peptide analogues with alanine substitutions.
Buku A; Mendlowitz M; Condie BA; Price JA
J Med Chem; 2003 Jul; 46(14):3008-12. PubMed ID: 12825939
[TBL] [Abstract][Full Text] [Related]
3. [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors.
Buku A; Condie BA; Price JA; Mezei M
J Pept Res; 2005 Sep; 66(3):132-7. PubMed ID: 16083440
[TBL] [Abstract][Full Text] [Related]
4. Effective mast cell degranulating peptide inhibitors of the IgE/Fc epsilonRI receptor interaction.
Buku A; Keselman I; Lupyan D; Mezei M; Price JA
Chem Biol Drug Des; 2008 Aug; 72(2):133-9. PubMed ID: 18624811
[TBL] [Abstract][Full Text] [Related]
5. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
[TBL] [Abstract][Full Text] [Related]
6. Further studies on the structural requirements for mast cell degranulating (MCD) peptide-mediated histamine release.
Buku A; Price JA
Peptides; 2001 Dec; 22(12):1987-91. PubMed ID: 11786181
[TBL] [Abstract][Full Text] [Related]
7. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of GmSubPep, a soybean peptide defense signal derived from an extracellular protease.
Pearce G; Munske G; Yamaguchi Y; Ryan CA
Peptides; 2010 Dec; 31(12):2159-64. PubMed ID: 20833217
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
10. A new FcεRI receptor-mimetic peptide (PepE) that blocks IgE binding to its high affinity receptor and prevents mediator release from RBL 2H3 cells.
Sandomenico A; Monti SM; Palumbo R; Ruvo M
J Pept Sci; 2011 Sep; 17(9):604-9. PubMed ID: 21538708
[TBL] [Abstract][Full Text] [Related]
11. Mast cell degranulating peptide binds to RBL-2H3 mast cell receptors and inhibits IgE binding.
Buku A; Price JA; Mendlowitz M; Masur S
Peptides; 2001 Dec; 22(12):1993-8. PubMed ID: 11786182
[TBL] [Abstract][Full Text] [Related]
12. Functional evidence for an intramolecular side chain interaction between residues 6 and 10 of receptor-bound parathyroid hormone analogues.
Shimizu N; Petroni BD; Khatri A; Gardella TJ
Biochemistry; 2003 Mar; 42(8):2282-90. PubMed ID: 12600195
[TBL] [Abstract][Full Text] [Related]
13. Mast cell degranulating (MCD) peptide analogs with reduced ring structure.
Buku A; Reibman J; Pistelli A; Blandina P; Gazis D
J Protein Chem; 1992 Jun; 11(3):275-80. PubMed ID: 1382440
[TBL] [Abstract][Full Text] [Related]
14. Bioactivities and secondary structure of mast cell degranulating (MCD) peptide analogs.
Buku A; Maulik G; Hook WA
Peptides; 1998; 19(1):1-5. PubMed ID: 9437730
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and binding properties of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues.
Tran TA; Mattern RH; Morgan BA; Taylor JE; Goodman M
J Pept Sci; 1999 Mar; 5(3):113-30. PubMed ID: 10323556
[TBL] [Abstract][Full Text] [Related]
16. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
[TBL] [Abstract][Full Text] [Related]
17. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
Sugaya M; Nishino N; Katoh A; Harada K
J Pept Sci; 2008 Aug; 14(8):924-35. PubMed ID: 18351707
[TBL] [Abstract][Full Text] [Related]
18. Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
Peptides; 2005 May; 26(5):887-91. PubMed ID: 15808919
[TBL] [Abstract][Full Text] [Related]
19. Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor.
Nakamura GR; Reynolds ME; Chen YM; Starovasnik MA; Lowman HB
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1303-8. PubMed ID: 11830661
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity studies of AtPep1, a plant peptide signal involved in the innate immune response.
Pearce G; Yamaguchi Y; Munske G; Ryan CA
Peptides; 2008 Dec; 29(12):2083-9. PubMed ID: 18824048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
